Dr. Allison Betof Warner on Outcomes With Anti-PD1 Therapy in Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.

Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, on responders to anti-PD1 therapy, including long-term outcomes and responses to retreatment in patients with melanoma. Warner presented this data (abstract 9513) at ASCO 2019.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma

IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma

Russ Conroy
November 8th 2024
Article

Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma

Russ Conroy
October 14th 2024
Article

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.

Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma

Megan Hollasch
September 17th 2024
Article

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.

Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.

IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma

Roman Fabbricatore
September 5th 2024
Article

Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.